THE ROLE OF SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS IN ACUTE MYOCARDIAL INFARCTION

Authors

  • D.A. Alimov

    Republican Scientific Center for Emergency Medical Care, Tashkent, Uzbekistan

    Author

  • R.P. Tulakov

    Kashkadarya Branch of the Republican Scientific Center for Emergency Medical Care, Karshi, Uzbekistan

    Author

  • A.K. Ergashеv

    Kashkadarya Branch of the Republican Scientific Center for Emergency Medical Care, Karshi, Uzbekistan

    Author

Keywords:
type 2 diabetes mellitus, acute myocardial infarction, complications, cardioprotection, treatment, sodium-glucose cotransporter-2 inhibitors, empagliflozin.
Abstract

This article analyzes the impact of sodium-glucose cotransporter-2 (SGLT2) inhibitors, particularly empagliflozin, on the course of acute myocardial infarction (AMI) in patients with type 2 diabetes mellitus (T2DM). Data are presented on the high prevalence of T2DM and its association with cardiovascular complications. The cardioprotective mechanisms of SGLT2 inhibitors are discussed, including the reduction of preload and afterload, improvement of myocardial metabolism, and antioxidant and anti-inflammatory effects. Randomized clinical trials (EMPA-REG OUTCOME, EMPEROR-Reduced) have demonstrated a reduction in cardiovascular mortality and hospitalization rates with SGLT2 inhibitors. However, their use in the acute phase of AMI remains insufficiently studied. The authors emphasize the need for further research to determine the optimal timing and conditions for their administration.

References

1.International Diabetes Federation. IDF Diabetes Atlas, 10th ed. Brussels, Belgium: International Diabetes Federation; 2021. Available at: https://www.diabetesatlas.org

2.Sobirova DR, Usmanov RD, Akhmedova DB. Monitoring glycated hemoglobin and glucose levels as an important factor in the treatment of experimental diabetes. Infection, Immunity, and Pharmacology. 2024;4:121–125. (In Russian).

3.Dedov II, Shestakova MV, Vikulova OK, Galstyan GR, Demidova TYu, Zaitseva EV. Atlas of the Diabetes Register of the Russian Federation. Status 2018. Diabetes Mellitus. 2019;22(2S):4–61. (In Russian). doi:10.14341/DM12208

4.Federal State Statistics Service of the Russian Federation. Healthcare in Russia, 2021. Published February 3, 2022. Available at: https://rosstat.gov.ru/folder/210/document/13218 (accessed February 3, 2025).

5.Nabi H, Kivimäki M, Batty GD, Shipley MJ, Britton A, Brunner EJ, et al. Increased risk of coronary heart disease among individuals reporting adverse impact of stress on their health: the Whitehall II prospective cohort study. Eur Heart J. 2013;34(34):2697–2705. doi:10.1093/eurheartj/eht216

6.American Diabetes Association. Diagnosis and classification of diabetes: Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(Suppl 1):S27–S49.

7.Desta L, Jernberg T, Löfman I, Hofman-Bang C, Hagerman I, Spaak J, et al. Incidence, temporal trends, and prognostic impact of heart failure complicating acute myocardial infarction: The SWEDEHEART Registry. J Am Coll Cardiol HF. 2015;3:234–242. doi:10.1016/j.jchf.2014.10.010

8.Peters SAE, Colantonio LD, Dai Y, Zhao H, Bittner V, Farkouh ME, et al. Trends in recurrent coronary heart disease after myocardial infarction among US women and men between 2008 and 2017. Circulation. 2021;143:650–660. doi:10.1161/CIRCULATIONAHA.120.049172

9.Giustino G, Redfors B, Brener SJ, Mehran R, Dangas GD, Feit F, et al. Correlates and prognostic impact of new-onset heart failure after ST-segment elevation myocardial infarction treated with primary PCI: Insights from INFUSE-AMI. Eur Heart J Acute Cardiovasc Care. 2018;7:339–347. doi:10.1177/2048872617744417

10.Bahit MC, Kochar A, Granger CB. Post-myocardial infarction heart failure.JAm Coll Cardiol HF. 2018;6:179–186. doi:10.1016/j.jchf.2017.10.009

11.Krumholz HM, Normand ST, Wang Y. Twenty-year trends in outcomes for older adults with acute myocardial infarction in the United States. JAMANetwOpen.2019;2:e191938.doi:10.1001/jamanetworkopen.2019.198

12.Desai NR, Udell JA, Wang Y, Spatz ES, Dharmarajan K, Ahmad T, et al. Trends in performance and opportunities for improvement on a composite measure of acute myocardial infarction care. Circ Cardiovasc QualOutcomes.2019;12:e004983.doi:10.1161/CIRCOUTCOMES.118.00493

13.Musaev TYa, Akhmedova NM, Tukhtaev AA. Use of sodium–glucose cotransporter 2 inhibitors in a young patient after acute myocardial infarction: a clinical case report. Central Asian Journal of Medical and Natural Science. 2023;4(5):497–505. (In Russian).

Downloads
Published
2026-02-24
Issue
Vol. 2 No. 2 (2026)
Section
Articles
License
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

THE ROLE OF SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS IN ACUTE MYOCARDIAL INFARCTION. (2026). Eureka Journal of Health Sciences & Medical Innovation, 2(2), 386-403. https://eurekaoa.com/index.php/5/article/view/515